Title: Atorvastatin is Widely Prescribed
1Atorvastatin is Widely Prescribed
- Atorvastatin has been approved in over 50
countries - More than 5.9 million patient years of
cholesterol-reducing therapy with atorvastatin
have been supplied worldwide since launch
IMS Jan 97Mar 99
2Adverse Event Profile for Atorvastatin
Atorvastatin (n2502)
Other statins combined (n742)
Atorvastatin adverse events experienced by ?2 of
patients
Includes 93 patients who received placebo for 16
weeks and then atorvastatin for 36
weeks. Simvastatin, lovastatin and
pravastatin. Includes 67 patients who received
placebo for 16 weeks and then lovastatin for 36
weeks. Black DM et al. Arch Intern Med
1998158577584.
3Atorvastatin vs Simvastatin
- Data from a 1-year comparative study showed that
- Atorvastatin was well-tolerated, with a safety
profile similar to that of simvastatin - 12 of atorvastatin patients had an adverse event
considered associated with treatment compared
with 16 of simvastatin patients - Most common adverse events with
- ? atorvastatin myalgia (3)
- ? simvastatin athralgia (7) and chest pain (4)
Data from a 1-year study comparing atorvastatin
1020 mg to simvastatin 1020 mg in 177
hypercholesterolemic patients. Dart A et al. Am J
Cardiol 1997803944.
4Atorvastatin vs Pravastatin
- Data from a 1-year comparative study
Atorvastatin is an efficacious HMG-CoA
reductase inhibitor that lowers LDL-C more
effectively than pravastatin within a similar
overall safety profile
Data from a 1-year study comparing atorvastatin
1020 mg to pravastatin 2040 mg in 305
hypercholesterolemic patients. Bertolini S et al.
Atherosclerosis 1997130191197.
5Atorvastatin vs Lovastatin
- Data from a 1-year comparative study
The overall safety profile of atorvastatin was
similar to that of lovastatin. Both compounds
were well tolerated
A 1-year study comparing atorvastatin 1020 mg to
lovastatin 2040 mg in 1049 hypercholesterolemic
patients Davidson M et al. Am J Cardiol
19977914751481.
6Atorvastatin vs Cerivastatin
- Data from a 6-week comparative study
Data from a 6-week study comparing atorvastatin
10 mg to cerivastatin 300 µg in 215
hypercholesterolemic patients. Hunninghake D et
al. Presented at the 71st European
Atherosclerosis Society Congress, 2629 May 1999,
Athens, Greece.
7Atorvastatin Safety Profile
- Review of 21 controlled clinical studies showed
that - ? ALT elevations gt3x ULN less than 1 of cases
- ? CPK gt10x ULN less than 0.1 of cases
- Controlled clinical trial data indicate that
atorvastatinhas no significant effect on
fibrinogen or Lp(a)
Black DM et al. Arch Intern Med
1998158577584. Davidson M et al. Am J Cardiol
19977914751481. Jones P et al. Am J Cardiol
199881582587.
8Safety in Special Populations
- Review of 21 clinical studies showed that the
safety profile of atorvastatin was comparable in - ? elderly vs non-elderly
- ? men vs women
- ? diabetics vs non-diabetics
Black DM et al. Arch Intern Med 1998158577574.
9Safety and Tolerability Conclusions
- Atorvastatin is well tolerated
- The safety profile of atorvastatin is similar to
that ofother statins - The safety profile of atorvastatin is similar
over a broadrange of patients